Effects of Levosimendan on Myocardial Infarct Size and Hemodynamics in a Closed-Chest Porcine Ischemia–Reperfusion Model

[1]  O. Baskurt,et al.  The Role of Potassium Channels in Relaxant Effect of Levosimendan in Rat Small Mesenteric Arteries , 2006, Cardiovascular Drugs and Therapy.

[2]  N. Freemantle,et al.  Clinical trials update from the American Heart Association: REPAIR‐AMI, ASTAMI, JELIS, MEGA, REVIVE‐II, SURVIVE, and PROACTIVE , 2006, European journal of heart failure.

[3]  E. Foster,et al.  Effects of Intravenous Levosimendan on Human Coronary Vasomotor Regulation, Left Ventricular Wall Stress, and Myocardial Oxygen Uptake , 2005, Circulation.

[4]  L. Lehtonen,et al.  The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. , 2004, Journal of the American College of Cardiology.

[5]  N. Freemantle,et al.  Clinical trials update and cumulative meta‐analyses from the American College of Cardiology: WATCH, SCD‐HeFT, DINAMIT, CASINO, INSPIRE, STRATUS‐US, RIO‐Lipids and cardiac resynchronisation therapy in heart failure , 2004, European journal of heart failure.

[6]  A. Kaltoft,et al.  Myocardial perfusion imaging with 99mTc sestamibi early after reperfusion reliably reflects infarct size reduction by ischaemic preconditioning in an experimental porcine model , 2004, Nuclear medicine communications.

[7]  H. Yokoshiki,et al.  Vasodilating Mechanisms of Levosimendan , 2003, Cardiovascular Drugs and Therapy.

[8]  J. Pataricza,et al.  Functional Role of Potassium Channels in the Vasodilating Mechanism of Levosimendan in Porcine Isolated Coronary Artery , 2003, Cardiovascular Drugs and Therapy.

[9]  V. Moiseyev,et al.  Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. a randomized, placebo-controlled, double-blind study (RUSSLAN) , 2003 .

[10]  T. LeJemtel,et al.  Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. , 2002, American heart journal.

[11]  R. Lange,et al.  Effect of the Calcium Sensitizer Levosimendan on the Performance of Ischaemic Myocardium in Anaesthetised Pigs , 2002, Cardiovascular Drugs and Therapy.

[12]  J. Cleland,et al.  Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial , 2002, The Lancet.

[13]  C. Slager,et al.  Calcium Sensitizer EMD 57033, But Not the &bgr; 1 -Adrenoreceptor Agonist Dobutamine, Increases Mechanical Efficiency in Stunned Myocardium , 2002, Journal of cardiovascular pharmacology.

[14]  E. D. du Toit,et al.  Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model , 2001, Heart.

[15]  P. Kaheinen,et al.  Improved survival with simendan after experimental myocardial infarction in rats. , 2001, European journal of pharmacology.

[16]  M. Nieminen,et al.  Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. , 2000, Journal of the American College of Cardiology.

[17]  S. Gottlieb,et al.  Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart Failure , 2000, Circulation.

[18]  P. Pagel,et al.  Levosimendan, a New Positive Inotropic Drug, Decreases Myocardial Infarct Size via Activation of KATP Channels , 2000, Anesthesia and analgesia.

[19]  L. Opie,et al.  Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. , 1999, The Journal of pharmacology and experimental therapeutics.

[20]  L. Toivonen,et al.  Effects of Levosimendan on Cardiac Arrhythmia: Electrophysiologic and Ambulatory Electrocardiographic Findings in Phase II and Phase III Clinical Studies in Cardiac Failure , 1999 .

[21]  C. Brookes,et al.  Intravenous magnesium reduces infarct size after ischemia/reperfusion injury combined with a thrombogenic lesion in the left anterior descending artery. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[22]  S. Sato,et al.  Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. , 1998, Journal of molecular and cellular cardiology.

[23]  J. Nielsen-Kudsk,et al.  Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. , 1998, Journal of cardiovascular pharmacology.

[24]  M. Nieminen,et al.  Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. , 1998, European heart journal.

[25]  M. Sunagawa,et al.  The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. , 1997, The Journal of pharmacology and experimental therapeutics.

[26]  R. V. Vander Heide,et al.  Epicardial temperature is a major predictor of myocardial infarct size in dogs. , 1997, Journal of molecular and cellular cardiology.

[27]  N. Alpert,et al.  Influence of isoproterenol and ouabain on excitation-contraction coupling, cross-bridge function, and energetics in failing human myocardium. , 1996, Circulation.

[28]  A. Branzi,et al.  Limitation of Myocardial Infarct Size by Nicorandil After Sustained Ischemia in Pigs , 1995, Journal of cardiovascular pharmacology.

[29]  J. Papp,et al.  Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. , 1995, Circulation research.

[30]  W. Klaus,et al.  Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts. , 1994, Pharmacology & toxicology.

[31]  G. Gross,et al.  Effects of the KATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. , 1994, Circulation.

[32]  G. Heusch,et al.  Development of Short‐term Myocardial Hibernation Its Limitation by the Severity of Ischemia and Inotropic Stimulation , 1993, Circulation.

[33]  B. Pitt,et al.  Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. , 1986, American heart journal.

[34]  S. David,et al.  Arrhythmias Associated with Intermittent Outpatient Dobutamine Infusion , 1986, Angiology.

[35]  F. C. White,et al.  Coronary collateral circulation in the pig: correlation of collateral flow with coronary bed size , 1981, Basic Research in Cardiology.

[36]  G. A. M. M. F. Frcpi.  The Myofilament Force-Calcium Relationship as a Target for Positive Inotropic Therapy in Congestive Heart Failure , 2005, Cardiovascular Drugs and Therapy.

[37]  S. Nielsen,et al.  Ischaemic preconditioning in the pig assessed by myocardial perfusion imaging and histochemistry. , 2003, APMIS. Supplementum.

[38]  J. Papp,et al.  STEERING COMMITTEE AND INVESTIGATORS OF THE LEVOSIMENDAN INFUSION VERSUS DOBUTAMINE (LIDO) STUDY. EFFICACY AND SAFETY OF INTRAVENOUS LEVOSIMENDAN COMPARED WITH DOBUTAMINE IN SEVERE LOWOUTPUT HEART FAILURE (THE LIDO STUDY): A RANDOMISED DOUBLEBLIND TRIAL , 2002 .

[39]  J. Nielsen-Kudsk,et al.  Will calcium sensitizers play a role in the treatment of heart failure? , 1995, Journal of cardiovascular pharmacology.